This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Alemany R, Balague C, Curiel DT . Replicative adenoviruses in cancer therapy. Nat Biotech 2000; 18: 723–727.
Kirn D . Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer. Oncogene 2000; 19: 6660–6669.
Ganley I et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res 2000; 6: 798–806.
Nemunaitis J et al. Selective replication an oncolysis in p53 mutant tumors with ONYX-015, and E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res 2000; 60: 6359–6366.
Papanastassoiu V et al. The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of priniciple study. Gene Ther 2002; 9: 398–406.
Caruso M et al. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc Natl Acad Sci USA 1993; 90: 7024–7028.
Khuri F et al. A controlled trial of intratumoural ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000; 6: 879–885.
Smith RR et al. Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer 1956; 9: 1211–1218.
Bischoff JR et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274: 373–376.
Yew PR, Liu X, Berk AJ . Adenovirus E1B oncoprotein tethers a transcriptional repression domain to p53. Genes Dev 1994; 8: 190–202.
Randazzo BP et al. Herpes simplex 1816 – an ICP 34.5 mutant – is severely replication restricted in human skin xenografts in vivo. Virology 1996; 223: 392–395.
Chong H et al. A system for small-molecule control of conditionally replication-competent adenoviral vectors. Mol Ther 2002; 5: 195–203.
Babiss LE, Freidman JM, Darnell JE . Cellular promoters incorporated into the adenovirus genome. Effect of viral DHA replication on endogenous and exogenous gene transcription. J Mol Biol 1987; 193: 643–650.
Dechecchi MC et al. Heparan sulfate glycosaminoglycans are receptors sufficient to medicate the initial binding of adenovirus types 2 and 5. J Virol 2001; 75: 8772–8780.
Qualikene W, Gonin P, Eloit M . Short and long term dissemination of deletion mutants of adenovirus in permissive (cotton rat) and non permissive (mouse) species. J Gen Virol 1994; 75: 2765–2768.
Ganly I, Mautner V, Balmain A . Productive replication of human adenoviruses in mouse epidermal cells. J Virol 2000; 75: 2895–2899.
Betts AO et al. Inoculation of pigs with adenovirus of man. Nature 1962; 193: 45–46.
Torres JM et al. Tropism of human adenovirus type 5-based vectors in swine and their ability to protect against transmissible gastroenteritis coronavirus. J Virol 1996; 70: 3770–3780.
Bogdanov A Jr., Weissleder R . In vivo imaging of gene delivery and expression. Trends Biotechnol 2002; 20: S11–S18.
Schellingerhout D et al. Quantitation of HSV mass distribution in a rodent brain tumor model. Gene Ther 2000; 7: 1648–1655.
Bennett JJ et al. Positron emission tomography imaging for herpes virus infection: implication for oncolytic viral treatments of cancer. Nat Med 2001; 7: 859–863.
Nemunaitis F et al. Phase II trial intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 2002; 19: 289–298.
Yver A . Does detection of circulating ONYX-015 genome by polymerase chain reaction indicate vector replication? J Clin Oncol 2001; 19: 3155–3157.
Acknowledgements
I thank Peter Harris, Chris Wrighton, David Kirn, William Wold, Richard Vile, Moira Brown, Martin Wisher, Norman Nevin, David Harrison, Alex Markham, Martin Gore, Terry Hamblin, Andrew Lever, Ian Hart, James Neil, Lawrence Young, Nick James, Peter Searle, Vivian Maunter, Paul Logan, Anthony Meager, Jayne Spink, Daniel Gooch and Margaret Straughan for their contributions to this forum and article.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Connolly, J. Conditionally replicating viruses in cancer therapy. Gene Ther 10, 712–715 (2003). https://doi.org/10.1038/sj.gt.3301898
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3301898
This article is cited by
-
Cancer immunotherapy: a paradigm shift for prostate cancer treatment
Nature Reviews Urology (2012)
-
Adenovirus as vehicle for anticancer genetic immunotherapy
Gene Therapy (2005)
-
Clostridia in cancer therapy
Nature Reviews Microbiology (2003)